SUBSEQUENT EVENTS (unaudited) (Details) $ in Thousands				1 Months Ended			3 Months Ended		6 Months Ended	12 Months Ended
	Aug. 06, 2020 USD ($)	Jul. 14, 2020 USD ($)	May 21, 2020 USD ($) month	Jul. 31, 2020 USD ($)	May 31, 2020 employee	Feb. 28, 2019 employee	Jun. 30, 2020 USD ($)	Mar. 31, 2019 USD ($)	Jun. 30, 2020 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)
Subsequent Event [Line Items]
Employees displaced through workforce reduction | employee						110
Restructuring charges								$ 7,400		$ 7,420	$ 0	$ 0
Subsequent Event
Subsequent Event [Line Items]
Employees displaced through workforce reduction | employee					110
Restructuring charges							$ 8,200
Agreement termination payment	$ 12,500
Option period to third party supplier to acquire study	9 months
Settlement awarded to other party		$ 17,400
Intrarosa | Millicent Pharma Limited | Subsequent Event
Subsequent Event [Line Items]
Proceeds related to collaborative arrangement			$ 20,900
Gain on sale of assets							$ 14,400		$ 14,400
Ciraparantag | Subsequent Event
Subsequent Event [Line Items]
Potential milestone proceeds from collaborative arrangement payable to equity holders				$ 40,000
Ciraparantag | Norgine B.V. | Subsequent Event
Subsequent Event [Line Items]
Proceeds related to collaborative arrangement				$ 30,000
Recovery of direct costs				33.00%
Vyleesi Products | Palatin Technologies, Inc. | Subsequent Event
Subsequent Event [Line Items]
Early contract termination fees				$ 12,000
Maximum | Intrarosa | Millicent Pharma Limited | Subsequent Event
Subsequent Event [Line Items]
Potential milestone proceeds from collaborative arrangement			105,000
First Time Net Sales During Threshold Period Exceeds $65 Million | Intrarosa | Millicent Pharma Limited | Subsequent Event
Subsequent Event [Line Items]
Potential milestone proceeds from collaborative arrangement			25,000
Potential milestone proceeds, triggering event, sales			$ 65,000
Consecutive period for sales to exceed threshold amount for potential milestone proceeds (in months) | month			12
First Time Net Sales During Threshold Period Exceeds $115 Million | Intrarosa | Millicent Pharma Limited | Subsequent Event
Subsequent Event [Line Items]
Potential milestone proceeds from collaborative arrangement			$ 35,000
Potential milestone proceeds, triggering event, sales			$ 115,000
Consecutive period for sales to exceed threshold amount for potential milestone proceeds (in months) | month			12
First Time Net Sales During Threshold Period Exceeds $175 Million | Intrarosa | Millicent Pharma Limited | Subsequent Event
Subsequent Event [Line Items]
Potential milestone proceeds from collaborative arrangement			$ 45,000
Potential milestone proceeds, triggering event, sales			$ 175,000
Consecutive period for sales to exceed threshold amount for potential milestone proceeds (in months) | month			12
Regulatory Milestone Achievement | Maximum | Ciraparantag | Norgine B.V. | Subsequent Event
Subsequent Event [Line Items]
Potential milestone proceeds from collaborative arrangement				70,000
Sales Milestones Achievement | Maximum | Ciraparantag | Norgine B.V. | Subsequent Event
Subsequent Event [Line Items]
Potential milestone proceeds from collaborative arrangement				190,000
Forecast | Vyleesi Products | Palatin Technologies, Inc. | Subsequent Event
Subsequent Event [Line Items]
Early contract termination fees				$ 4,300